Screener
Syndax Pharmaceuticals SNDX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $130,893 | $134,930 |
| Short-term investments | 221,171 | 259,140 |
| Accounts receivable | 38,116 | 37,996 |
| Inventory, net | 34,948 | 32,754 |
| Short-term deposits | 9,175 | 19,616 |
| Other receivables, net | 267 | 6,404 |
| Collaboration receivable, net | 20,507 | 23,745 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's accounts receivable?
- Syndax Pharmaceuticals (SNDX) reported accounts receivable of $38.12M in Q1 2026.
- How has Syndax Pharmaceuticals's accounts receivable changed year-over-year?
- Syndax Pharmaceuticals's accounts receivable increased by 142.4% year-over-year, from $15.72M to $38.12M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Syndax Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude